[
  {
    "ts": "2026-02-12T00:49:28+00:00",
    "headline": "Evercore ISI Cuts AbbVie Inc. (ABBV) PT, Says Consensus for 2026 and 2027 Still Looks Beatable",
    "summary": "AbbVie Inc. (NYSE:ABBV) is included among the 13 Best Roth IRA Stocks to Buy Now. On February 5, Evercore ISI analyst Gavin Clark-Gartner trimmed his price recommendation on AbbVie Inc. (NYSE:ABBV) to $228 from $232. The analyst maintained an Outperform rating on the stock. In a note to investors, he said that despite Tremfya continuing [因",
    "url": "https://finance.yahoo.com/news/evercore-isi-cuts-abbvie-inc-004928355.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "bf64bd40-dd83-36b5-aa1d-e9d8fd56e504",
      "content": {
        "id": "bf64bd40-dd83-36b5-aa1d-e9d8fd56e504",
        "contentType": "STORY",
        "title": "Evercore ISI Cuts AbbVie Inc. (ABBV) PT, Says Consensus for 2026 and 2027 Still Looks Beatable",
        "description": "",
        "summary": "AbbVie Inc. (NYSE:ABBV) is included among the 13 Best Roth IRA Stocks to Buy Now. On February 5, Evercore ISI analyst Gavin Clark-Gartner trimmed his price recommendation on AbbVie Inc. (NYSE:ABBV) to $228 from $232. The analyst maintained an Outperform rating on the stock. In a note to investors, he said that despite Tremfya continuing [因",
        "pubDate": "2026-02-12T00:49:28Z",
        "displayTime": "2026-02-12T00:49:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Evercore ISI Cuts AbbVie Inc. (ABBV) PT, Says Consensus for 2026 and 2027 Still Looks Beatable",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aXAa28AvezyRv056g_RUEg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lzVMSqWRbEKelBHS4c050A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/evercore-isi-cuts-abbvie-inc-004928355.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/evercore-isi-cuts-abbvie-inc-004928355.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-12T09:42:38+00:00",
    "headline": "AbbVie Inc. (ABBV) Achieves Record Net Sales  on Diversified Growth Platform",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best long-term stocks to invest in for retirement. On February 6, Cantor Fitzgerald reiterated its Overweight rating on AbbVie Inc. (NYSE:ABBV) with a $250 price target. The positive outlook follows solid fourth-quarter 2025 results, as Skyrizi sales topped estimates and the company provided guidance above consensus. On February [因",
    "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-achieves-record-094238505.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "ef63046f-d04f-3e1e-9062-f78742afa42d",
      "content": {
        "id": "ef63046f-d04f-3e1e-9062-f78742afa42d",
        "contentType": "STORY",
        "title": "AbbVie Inc. (ABBV) Achieves Record Net Sales  on Diversified Growth Platform",
        "description": "",
        "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best long-term stocks to invest in for retirement. On February 6, Cantor Fitzgerald reiterated its Overweight rating on AbbVie Inc. (NYSE:ABBV) with a $250 price target. The positive outlook follows solid fourth-quarter 2025 results, as Skyrizi sales topped estimates and the company provided guidance above consensus. On February [因",
        "pubDate": "2026-02-12T09:42:38Z",
        "displayTime": "2026-02-12T09:42:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/d286e8ba05d14927faa0783c78adbf83",
          "originalWidth": 250,
          "originalHeight": 200,
          "caption": "AbbVie Inc. (ABBV) Achieves Record Net Sales  on Diversified Growth Platform",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4CLlW5d8JqECr37AWqo_rA--~B/aD0yMDA7dz0yNTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/d286e8ba05d14927faa0783c78adbf83.cf.webp",
              "width": 250,
              "height": 200,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hvMeAsl9tUIOK2KJa22_lA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/d286e8ba05d14927faa0783c78adbf83.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-achieves-record-094238505.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-achieves-record-094238505.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-12T10:04:00+00:00",
    "headline": "1 Reason I'm Never Selling AbbVie Stock",
    "summary": "This Dividend King has staying power.",
    "url": "https://www.fool.com/investing/2026/02/12/1-reason-im-never-selling-abbvie-stock/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "48f42e3b-889d-38d0-85d0-ce1d6fc5e843",
      "content": {
        "id": "48f42e3b-889d-38d0-85d0-ce1d6fc5e843",
        "contentType": "STORY",
        "title": "1 Reason I'm Never Selling AbbVie Stock",
        "description": "",
        "summary": "This Dividend King has staying power.",
        "pubDate": "2026-02-12T10:04:00Z",
        "displayTime": "2026-02-12T10:04:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/f61da062ac1d0dddefd1117a5bcae2fd",
          "originalWidth": 1024,
          "originalHeight": 683,
          "caption": "AbbVie sign in front of a building.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KMzP9YnP4cEbcAXd_3GoqA--~B/aD02ODM7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/f61da062ac1d0dddefd1117a5bcae2fd.cf.webp",
              "width": 1024,
              "height": 683,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/v_z5QfZ_BSegzEi3GN.9XA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/f61da062ac1d0dddefd1117a5bcae2fd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/12/1-reason-im-never-selling-abbvie-stock/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-reason-im-never-selling-100400371.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-12T12:14:48+00:00",
    "headline": "Is It Too Late To Consider AbbVie (ABBV) After Its Strong Multi Year Run?",
    "summary": "If you are wondering whether AbbVie shares still offer value after a strong multi year run, this article walks through what the current price might be implying. The stock last closed at US$220.89, with returns of 1.7% over 7 days, 0.4% over 30 days, a 3.7% decline year to date, 18.3% over 1 year, 63.0% over 3 years and 151.6% over 5 years. Recent headlines around AbbVie have focused on its large cap pharmaceutical profile and on how investors are weighing its long term product portfolio...",
    "url": "https://finance.yahoo.com/news/too-consider-abbvie-abbv-strong-121448904.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "0de84ed5-7406-31a3-aee9-7c7bcfe2744b",
      "content": {
        "id": "0de84ed5-7406-31a3-aee9-7c7bcfe2744b",
        "contentType": "STORY",
        "title": "Is It Too Late To Consider AbbVie (ABBV) After Its Strong Multi Year Run?",
        "description": "",
        "summary": "If you are wondering whether AbbVie shares still offer value after a strong multi year run, this article walks through what the current price might be implying. The stock last closed at US$220.89, with returns of 1.7% over 7 days, 0.4% over 30 days, a 3.7% decline year to date, 18.3% over 1 year, 63.0% over 3 years and 151.6% over 5 years. Recent headlines around AbbVie have focused on its large cap pharmaceutical profile and on how investors are weighing its long term product portfolio...",
        "pubDate": "2026-02-12T12:14:48Z",
        "displayTime": "2026-02-12T12:14:48Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cbaG7tZ9A8mqrilci3AeIQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1OA9tdPdimVe1Dv1fa4MAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/too-consider-abbvie-abbv-strong-121448904.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/too-consider-abbvie-abbv-strong-121448904.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]